TRAW Valuation

Traws Pharma Inc

Add to Watchlist

Advanced Chart

1.610

+0.17(11.806%)1D

Overview
Forecast
Valuation
Earnings

TRAW Relative Valuation

TRAW's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TRAW is overvalued; if below, it's undervalued.

Historical Valuation

Traws Pharma Inc (TRAW) is now in the Fair zone, suggesting that its current forward PS ratio of 43.00 is considered Fairly compared with the five-year average of -12.67. The fair price of Traws Pharma Inc (TRAW) is between 0.91 to 2.40 according to relative valuation methord.

Relative Value

Fair Zone

0.91-2.40

Current Price：1.58

Fair

-0.04

Trailing

Forward

0.11

EV/EBITDA

Traws Pharma Inc. (TRAW) has a current EV/EBITDA of 0.11. The 5-year average EV/EBITDA is -0.75. The thresholds are as follows: Strongly Undervalued below -6.77, Undervalued between -6.77 and -3.76, Fairly Valued between 2.27 and -3.76, Overvalued between 2.27 and 5.28, and Strongly Overvalued above 5.28. The current Forward EV/EBITDA of 0.11 falls within the Historic Trend Line -Fairly Valued range.

0.11

EV/EBIT

Traws Pharma Inc. (TRAW) has a current EV/EBIT of 0.11. The 5-year average EV/EBIT is -0.79. The thresholds are as follows: Strongly Undervalued below -6.97, Undervalued between -6.97 and -3.88, Fairly Valued between 2.30 and -3.88, Overvalued between 2.30 and 5.39, and Strongly Overvalued above 5.39. The current Forward EV/EBIT of 0.11 falls within the Historic Trend Line -Fairly Valued range.

43.00

Traws Pharma Inc. (TRAW) has a current PS of 43.00. The 5-year average PS is 191.39. The thresholds are as follows: Strongly Undervalued below -361.53, Undervalued between -361.53 and -85.07, Fairly Valued between 467.85 and -85.07, Overvalued between 467.85 and 744.31, and Strongly Overvalued above 744.31. The current Forward PS of 43.00 falls within the Historic Trend Line -Fairly Valued range.

0.03

P/OCF

Traws Pharma Inc. (TRAW) has a current P/OCF of 0.03. The 5-year average P/OCF is 0.07. The thresholds are as follows: Strongly Undervalued below -0.42, Undervalued between -0.42 and -0.18, Fairly Valued between 0.31 and -0.18, Overvalued between 0.31 and 0.56, and Strongly Overvalued above 0.56. The current Forward P/OCF of 0.03 falls within the Historic Trend Line -Fairly Valued range.

0.06

P/FCF

Traws Pharma Inc. (TRAW) has a current P/FCF of 0.06. The 5-year average P/FCF is 0.26. The thresholds are as follows: Strongly Undervalued below -1.80, Undervalued between -1.80 and -0.77, Fairly Valued between 1.29 and -0.77, Overvalued between 1.29 and 2.32, and Strongly Overvalued above 2.32. The current Forward P/FCF of 0.06 falls within the Historic Trend Line -Fairly Valued range.

Traws Pharma Inc (TRAW) has a current Price-to-Book (P/B) ratio of 1.23. Compared to its 3-year average P/B ratio of -0.23 , the current P/B ratio is approximately -629.60% higher. Relative to its 5-year average P/B ratio of 2.10, the current P/B ratio is about -41.42% higher. Traws Pharma Inc (TRAW) has a Forward Free Cash Flow (FCF) yield of approximately -272.33%. Compared to its 3-year average FCF yield of -159.89%, the current FCF yield is approximately 70.32% lower. Relative to its 5-year average FCF yield of -110.58% , the current FCF yield is about 146.28% lower.

1.23

P/B

Median3y

-0.23

Median5y

2.10

-272.33

FCF Yield

Median3y

-159.89

Median5y

-110.58

Competitors Valuation Multiple

The average P/S ratio for TRAW's competitors is 8.62, providing a benchmark for relative valuation. Traws Pharma Inc Corp (TRAW) exhibits a P/S ratio of 43.00, which is 398.95% above the industry average. Given its robust revenue growth of 4694.74%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Sensei Biotherapeutics Inc

CERo Therapeutics Holdings Inc

Loss

8.92M

Performance Decomposition

Market capitalization of TRAW decreased by 73.96% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 57.00K to 2.73M.

The secondary factor is the Margin Expansion, contributed -99.98%to the performance.

Overall, the performance of TRAW in the past 1 year is driven by Revenue Growth. Which is more sustainable.

4694.74%

57.00K → 2.73M

Revenue Growth

-99.98%

-216.04K → -33.48

Margin Expansion

-4668.72%

0.03 → -1.34

P/E Change

-73.96%